Pharmacokinetics and pharmacodynamics of AJW200, a humanized monoclonal antibody to von Willebrand factor, in monkeys

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 22, Issue 1, 2002, Pages 187-192

  Kageyama, Shunsuke ^a   Yamamoto, Hiroshi ^a   Nakazawa, Harumi ^a   Matsushita, Junko ^a   Kouyama, Tetsuya ^a   Gonsho, Akinori ^a   Ikeda, Yasuo ^a   Yoshimoto, Ryota ^a  

^a NONE   (Japan)

Author keywords

AJW200; Bleeding time; Platelets; Shear stress; Von Willebrand factor

Indexed keywords

ABCIXIMAB; GLYCOPROTEIN IB; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY AJW200; RISTOCETIN; THROMBIN; UNCLASSIFIED DRUG; VON WILLEBRAND FACTOR;

ARTICLE; BLEEDING TIME; DOSE RESPONSE; HUMAN; HUMAN CELL; NONHUMAN; PHARMACODYNAMICS; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; SHEAR STRESS; THROMBOCYTE ADHESION; THROMBOCYTE AGGREGATION; THROMBOCYTE AGGREGATION INHIBITION; THROMBOGENESIS; THROMBOSIS;

ANIMALS; ANTIBODIES, MONOCLONAL; BLEEDING TIME; BLOOD PLATELETS; HEMORHEOLOGY; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; MACACA FASCICULARIS; PLATELET ADHESIVENESS; PLATELET AGGREGATION; PLATELET GLYCOPROTEIN GPIB-IX COMPLEX; RISTOCETIN; THROMBIN; VON WILLEBRAND FACTOR;

EID: 0036141796     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/hq0102.101520     Document Type: Article

References (17)

1. Randomized trial of coronary intervention with antibody against platelet IIb/IIIa integrin for reduction of clinical restenosis: Results at six months
2. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization
3. Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade
4. Human blood platelet adhesion to artery subendothelium is mediated by factor VII-von Willebrand factor bound to the subendothelium
5. Platelet adhesion to collagen in subtypes of type I von Willebrand's disease is dependent on platelet von Willebrand factor
6. Aurintricarboxylic acid in a canine model of coronary artery thrombosis
7. Abolition of cyclic flow variations in stenosed, endothelium-injured coronary arteries in nonhuman primates with a peptide fragment (VCL) derived from human plasma von Willebrand factor-glycoprotein Ib binding domain
8. Anti-thrombotic effects and bleeding risk of AJvW-2, a monoclonal antibody against human von Willebrand factor
9. Antagonism of vWF inhibits both injury induced arterial and venous thrombosis in the hamster
10. Anti-human von Willebrand factor monoclonal antibody AJvW-2 prevents thrombus deposition and neointima formation after balloon injury in guinea pigs
11. Anti-human vWF monoclonal antibody, AJvW-2 Fab, inhibits repetitive coronary artery thrombosis without bleeding time prolongation in dogs
12. Enhanced shear-induced platelet aggregation in acute myocardial infarction
13. AJvW-2, an anti-vWF monoclonal antibody, inhibits enhanced platelet aggregation induced by high shear stress in platelet-rich plasma from patients with acute coronary syndromes
14. The role of von Willebrand factor and fibrinogen in platelet aggregation under varying shear stress
15. Inhibition of platelet-mediated, tissue factor-induced thrombin generation by the mouse/human chimeric 7E3 antibody: Potential implications for the effect of c7E3 Fab treatment on acute thrombosis and 'clinical restenosis'
16. Lack of usefulness of prolonged bleeding times in predicting hemorrhagic events in patients receiving the 7E3 glycoprotein IIb/IIIa platelet antibody
17. Comprehensive pharmacokinetics of a humanized antibody and analysis of residual anti-idiotypic responses